

UK Antimicrobial Registry (UKAR): Now and Next

Study Coordinators: Rebecca Parr and Jisha Babu



Epidemiology Group – School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, UK

UK Antimicrobial Registry

- Drug registry looking at effectiveness and safety of recently licensed antimicrobials
- Open to recruitment from May 2023
- Supports antimicrobial stewardship of new agents

Inclusion criteria	Exclusion criteria
1. Patient prescribed any eligible study drug during current hospital stay.	1. Prescription of study drug was >60 days prior to recruitment.
2. Person consenting (patient or proxy) able to understand the consent process.	2. Patient was aged <18yrs on the first day of prescription with study drug.

Study update


- Reached site recruitment target of 50 sites.
- On track to recruit over 1,000 participants
- Addition of 2 new Gram-negative drugs → now 13 eligible study drugs
 - Aztreonam/avibactam
 - Cefepime/enmetazobactam

Data, as of 30th April 2025

- **Recruitment centres:**
 - 51 sites actively recruiting participants
- **Participants:**
 - 808 patients consented to participate
 - 10 of 13 study drugs represented
 - Majority (N = 282) prescribed dalbavancin
- **Most frequently recorded infections:**
 - Lower respiratory tract infection (25%)
 - Skin and subcutaneous tissue infection (17%)
 - Systemic infections & conditions incl. Sepsis (17%)

What next?

- Ongoing data collection
- Data analysis
- Manuscript of data from first 20 months
- Exploring options for expansion
- Data being presented on Friday 16th May 2025
 - **Session Ten: The Delinkage Model**



Study drug	N (%)	Characteristics
GRAM-POSITIVE		
• Ceftaroline	25 (3%)	Median age 55yrs (range 42-69yrs) 41% female
• Ceftobiprole	5 (<1%)	
• Dalbavancin	282 (36%)	
• Delafloxacin	3 (<1%)	
• Oritavancin	2 (<1%)	
GRAM-NEGATIVE		
• Cefiderocol	125 (16%)	Median age 62yrs (range 46-72yrs) 43% female
• Ceftazidime/avibactam	198 (25%)	
• Ceftolozane/tazobactam	99 (13%)	
• Imipenem/cilastatin/relebactam	30 (4%)	
• Meropenem/vaborbactam	12 (1.5%)	
• Eravacycline	-	

For further information,
or to sign up:

abdn.ac.uk/ukar

